Pfizer set to double weekly production of coronavirus vaccine
Bio Pharma Dive
FEBRUARY 19, 2021
The drugmaker will use production lines at its plant in McPherson, Kansas to help fill vaccine vials, company CEO Albert Bourla said Friday.
Dyadic expands Covid-19 licence with Rubic to bolster vaccine production in Africa
Pharmaceutical Technology
APRIL 13, 2023
The expanded licence will include the development of vaccines and therapeutic proteins beyond Covid-19 for human and animal health markets in Africa. During the Covid-19 pandemic, vaccination rates of many countries in Africa were significantly trailing the rest of the world.
Production 
279
279 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Croda Pharma and BSI partner for vaccine adjuvant QS-21 production
Pharmaceutical Technology
MAY 23, 2023
Croda Pharma has entered a strategic collaboration deal with Botanical Solution Inc (BSI) to expedite the production of sustainable pharmaceutical-grade vaccine adjuvant QS-21. The plentiful supply of QS-21 enables the production of next-generation adjuvant systems for new vaccine development.”
Vaccine 240
240 
Pfizer forecasts $26B in coronavirus vaccine revenue this year
Bio Pharma Dive
MAY 4, 2021
The sum is $11 billion higher than Pfizer had estimated in February and, if realized, would make the vaccine the highest grossing pharmaceutical product by revenue in a single year.
Vaccine 333
333 
Vaccine production in focus as Moderna, Pfizer await FDA decision
Bio Pharma Dive
DECEMBER 4, 2020
Moncef Slaoui, a leader of Operation Warp Speed, said he expects 100 million Americans to be vaccinated by the end of February — an ambitious target even as Moderna and Pfizer ramp up manufacturing.
Vaccine 257
257 
UNICEF secures one million mpox vaccines for Africa
Pharmaceutical Technology
SEPTEMBER 27, 2024
Bavarian Nordic has already said it would prioritise mpox vaccine production to fulfil orders this year.
Vaccine 264
264 
How did pharma develop a vaccine so quickly?
World of DTC Marketing
DECEMBER 29, 2020
OBSERVATION: Biologics can take a long time to develop but COVID vaccines have been in development for almost 50 years and novel approaches were used to develop these vaccines. Vaccines typically take 10 to 15 years to develop, test and release to the public. The coronavirus vaccines, however, took less than a year.
Vaccine 307
307 
Drugmakers push forward on large-scale production of coronavirus vaccines
Bio Pharma Dive
SEPTEMBER 24, 2020
HHS Secretary Alex Azar said six vaccine developers involved with Operation Warp Speed had begun commercial manufacturing of their experimental shots.
Vaccine 234
234 
J&J to oversee vaccine production at Emergent factory that ruined doses
Bio Pharma Dive
APRIL 5, 2021
The change, which follows the contractor's costly manufacturing mix-up, will displace production of AstraZeneca's unauthorized shot at the Baltimore site.
Production 246
246 
India grants approval for Bharat Biotech’s intranasal Covid-19 vaccine
Pharmaceutical Technology
SEPTEMBER 7, 2022
Indian company Bharat Biotech International has secured approval from Central Drugs Standard Control Organisation (CDSCO) under Restricted Use in Emergency Situation for its intranasal Covid-19 vaccine, iNCOVACC (BBV154), for usage in people aged 18 years and older. It is formulated to permit intranasal delivery via nasal drops.
Vaccine 263
263 
SK Bioscience gains UK authorisation for SKYCovion Covid-19 vaccine
Pharmaceutical Technology
MAY 30, 2023
SK Bioscience has received marketing authorisation from the UK’s medicines and healthcare products regulatory agency (MHRA) for its Covid-19 vaccine, SKYCovion. The authorisation allows the distribution of the vaccine in Scotland, Wales and England.
Vaccine 298
298 
EU speeds approval of monkeypox vaccine as WHO declares public health emergency
Bio Pharma Dive
JULY 25, 2022
Vaccine maker Bavarian Nordic said it is meeting demand for its shot with production capacity of 30 million doses a year.
Vaccine 271
271 
BioNTech targets infectious diseases for vaccine development
Pharmaceutical Technology
MARCH 28, 2023
Following on from its Covid-19 vaccine programmes, BioNTech has set its sights on a range of infectious diseases for vaccine development. The company saw major successes with its Covid-19 vaccine, developed in collaboration with Pfizer. In response to the lower vaccine sales forecasts, BioNTech shares opened at 3.9%
Vaccine 276
276 
Moderna sues Pfizer, BioNTech over COVID-19 vaccine technology
Bio Pharma Dive
AUGUST 26, 2022
The biotech claims its rivals’ vaccine Comirnaty, one of the world’s top-selling pharmaceutical products, infringes on two patents covering its messenger RNA technology.
Vaccine 259
259 
UK MHRA approves Takeda’s dengue vaccine Qdenga
Pharmaceutical Technology
FEBRUARY 7, 2023
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Takeda ’s dengue virus vaccine candidate, Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]). The vaccine candidate has been approved for active immunisation against the infection in people from four years of age.
Vaccine 264
264 
China NMPA grants approval for CanSinoBIO’s Covid-19 vaccine as booster
Pharmaceutical Technology
SEPTEMBER 5, 2022
The National Medical Products Administration of China (NMPA) has approved CanSino Biologics ’ (CanSinoBIO) recombinant Covid-19 vaccine (Adenovirus Type 5 Vector) for inhalation, Convidecia Air, as a booster. This vaccine leverages the same adenovirus vector technological platform as Convidecia, the intramuscular version.
Vaccine 264
264 
Moderna signs contract to supply Covid-19 booster vaccines to the US
Pharmaceutical Technology
AUGUST 1, 2022
Moderna has entered a new supply contract with the US Government to deliver 66 million doses of its Covid-19 vaccine booster candidate, mRNA-1273.222. The contract comprises a $1.74bn award to produce and supply these vaccine doses and options to further procure up to 234 million additional doses of the company’s booster candidates.
Vaccine 289
289 
MSD expands vaccine production with new $1bn facility
Pharmaceutical Technology
MARCH 11, 2025
MSD has opened a $1bn facility in Durham located in the US state of North Carolina, to increase vaccine manufacturing capacity.
Vaccine 147
147 
Samsung Biologics, GreenLight conclude Covid-19 vaccine engineering run
Pharmaceutical Technology
AUGUST 2, 2022
Samsung Biologics and GreenLight Biosciences have completed the initial commercial-scale engineering run for their messenger ribonucleic acid (mRNA) Covid-19 vaccine under their manufacturing collaboration. Following the demonstration at Samsung, the clinical trial of GreenLight’s Covid-19 booster vaccine is anticipated to commence this year.
Engineer 262
262 
Covid vaccine profits and the strain on supply channels
World of DTC Marketing
JANUARY 8, 2021
SUMMARY: Pfizer and Moderna will sell $28 billion of Covid-19 vaccines this year. Pharma companies will make an estimated $40 billion on the global COVID-19 vaccine market this year, which will be split between Johnson & Johnson, AstraZeneca, Novavax, and others. Can the FDA really control the quality of vaccine orders this big?
Vaccine 266
266 
US FDA grants Fast Track status for Pfizer-BioNTech’s combination vaccine
Pharmaceutical Technology
DECEMBER 11, 2022
The US Food and Drug Administration (FDA) has granted Fast Track designation for Pfizer and BioNTech’s messenger ribonucleic acid (mRNA)-based combination vaccine candidate against Covid-19 and influenza. The vaccine is intended to prevent two respiratory ailments through a single injection. 5 Omicron sublineages spike proteins.
Vaccine 289
289 
BARDA awards contract for Sabin’s Ebola Sudan and Marburg virus vaccines
Pharmaceutical Technology
JANUARY 13, 2023
The Biomedical Advanced Research and Development Authority (BARDA) has awarded a multi-year contract to the Sabin Vaccine Institute for developing and producing single-dose vaccine candidates for Ebola Sudan and Marburg virus diseases. Currently, there are no licensed vaccines against these viruses.
Vaccine 246
246 
Moderna readies multi-pronged plan for coronavirus variants, ups vaccine production
Bio Pharma Dive
FEBRUARY 24, 2021
The biotech has delivered a newly developed booster shot to NIH scientists, and will test several other approaches to address emerging virus strains.
Production 264
264 
HIV vaccines suffer setbacks but new approaches could turn the tide
Pharmaceutical Technology
FEBRUARY 3, 2023
Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.
Vaccine 293
293 
EC approves Novavax’s Covid-19 vaccine CMA expansion for adolescents
Pharmaceutical Technology
JULY 6, 2022
The European Commission (EC) has granted approval for the expanded conditional marketing authorization (CMA) of Novavax’s Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), in the European Union (EU) for adolescents of the age 12 to 17 years. A protein-based vaccine, NVX-CoV2373 is made from the genetic sequence of the SARS-CoV-2 virus’ first strain.
Vaccine 264
264 
GreenLight and US NIH partner to develop Covid-19 vaccine for variants
Pharmaceutical Technology
AUGUST 1, 2022
GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.
Vaccine 245
245 
Novavax’s Covid-19 vaccine gets Taiwan FDA EUA for use in adults
Pharmaceutical Technology
JUNE 24, 2022
Novavax has obtained emergency use authorization (EUA) for its Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), from the Taiwan Food and Drug Administration for use in people of the age 18 years and above. The protein-based vaccine is engineered from the genetic sequence of the SARS-CoV-2 virus’ initial strain.
Vaccine 263
263 
GSK confident in RSV vaccine launch, but sets expectations for ‘steady build’
Bio Pharma Dive
JULY 27, 2023
GSK expects its respiratory syncytial virus vaccine will be a multibillion dollar product. But at the beginning it’s predicting a slower launch than for its fast-selling shingles shot.
Vaccine 246
246 
Health Canada grants approval for Moderna’s Covid-19 vaccine in children
Pharmaceutical Technology
JULY 15, 2022
Health Canada has granted approval for the usage of Moderna’s messenger RNA (mRNA) Covid-19 vaccine, Spikevax, in a 25µg two-dose regimen for active immunisation to prevent Covid-19 in children aged six months to five years. So far, children aged below five years were not eligible to receive the Covid-19 vaccine in Canada.
Vaccine 264
264 
Catalent, seeing rising demand, to expand Indiana production plant
Bio Pharma Dive
SEPTEMBER 3, 2020
The planned $50 million infusion is the third investment in Catalent's Bloomington facility in two years, reflecting the need for vial filling for biologic drugs and vaccines.
Production 246
246 
RVAC and University of Pennsylvania to develop mRNA vaccines
Pharmaceutical Technology
MARCH 20, 2023
RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The mRNA vaccine candidates will help reduce the chances of autoimmune responses that might lead to allergic conditions or serious autoimmune diseases.
Vaccine 245
245 
GSK wagers $2.1B on Affinivax and its next-generation pneumonia vaccine
Bio Pharma Dive
MAY 31, 2022
The deal is the second acquisition for GSK since April and gives the company access to an experimental shot that’s meant to surpass new products from Pfizer and Merck & Co.
Vaccination 333
333 
GenScript ProBio and RVAC partner for Covid-19 vaccine pDNA
Pharmaceutical Technology
FEBRUARY 23, 2023
GenScript ProBio has announced a strategic collaboration with RVAC Medicines to manufacture GMP-grade plasmid DNA (pDNA) for the latter’s RVM-V001, an mRNA Covid-19 vaccine candidate. The post GenScript ProBio and RVAC partner for Covid-19 vaccine pDNA appeared first on Pharmaceutical Technology.
Vaccine 289
289 
WHO grants emergency use listing to SK bioscience’s SKYCovione
Pharmaceutical Technology
JUNE 20, 2023
The World Health Organisation (WHO) has granted an emergency use listing (EUL) to SK bioscience’s Covid-19 vaccine, SKYCovione. SKYCovione is a self-assembled nanoparticle vaccine and the 12th Covid-19 vaccine to receive a EUL from the regulator.
Vaccine 363
363 
Moderna cuts sales forecasts for its COVID-19 vaccine
Bio Pharma Dive
NOVEMBER 3, 2022
The biotech dialed back its financial projections after reporting lower-than-expected sales for the shot, which currently remains the company’s only marketed product.
Sales 297
297 
Gates Foundation spends $40M to boost mRNA vaccine production in Africa and beyond
Fierce Pharma
OCTOBER 9, 2023
Following similar initiatives to bolster mRNA vaccine production and access in Africa, the Bill & Melinda Gates Foundation is providing new funding to a clutch of drugmakers.
Production 133
133 
Pfizer’s Covid-19 vaccine sales forecasts upgraded with sales of $37bn in 2022
Pharmaceutical Technology
FEBRUARY 21, 2023
Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, had a phenomenal year with forecast sales of $37bn in 2022. Comirnaty is the leading prophylactic vaccine for Covid-19 and is expected to generate an additional $2.8bn in sales in 2022 compared to GlobalData’s H1 2022 forecast. Comirnaty is the first globally approved Covid-19 vaccine.
Sales 246
246 
AstraZeneca plans for adapting vaccine to coronavirus variants, but offers longer timeline than rivals
Bio Pharma Dive
FEBRUARY 11, 2021
The drugmaker says between six to nine months are needed to ramp up production of an adapted shot. South Africa recently stopped using the vaccine due to its reduced potency against a common strain there.
Vaccine 211
211 
UK MHRA grants authorisation for Moderna’s Covid-19 booster vaccine
Pharmaceutical Technology
AUGUST 15, 2022
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional authorisation for Moderna ’s Covid-19 booster vaccine, mRNA-1273.214 (Spikevax Bivalent Original/Omicron), for use in adults aged 18 years and above. In addition, no serious safety concerns linked to the vaccine were observed.
Vaccine 214
214 
Moderna, chasing GSK and Pfizer, brings RSV vaccine to regulators
Bio Pharma Dive
JULY 5, 2023
The vaccine has a chance to become Moderna’s second approved product and could help offset declining sales for its COVID-19 shot.
Vaccine 180
180 
Meningitis vaccine comes to the forefront with impressive study results
Pharmaceutical Technology
MAY 25, 2023
A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. percentage points (96% CI, −0.3
Vaccine 195
195 
Pfizer RSV vaccine gets off to fast start on market
Bio Pharma Dive
OCTOBER 31, 2023
The pharma’s shot Abrysvo made over $300 million in sales during the first few months of its launch, and will be an important product to help offset declining COVID vaccine sales.
Vaccine 180
180 
Moderna, trailing rivals, checks its RSV shot expectations
Bio Pharma Dive
SEPTEMBER 13, 2024
During an investor presentation Thursday, executives admitted to being overly optimistic their vaccine could wrest significant market share away from GSK's and Pfizer's products this year.
Vaccine 270
270 
Croda and Botanical Solution Inc. (BSI) partner to fast-track sustainable vaccine adjuvant QS-21 production
Pharma Mirror
MAY 23, 2023
QS-21 is used in several innovative vaccines against diseases such as shingles, malaria and RSV, plus promising new vaccine and immunotherapy treatments such as cancer. BSI) partner to fast-track sustainable vaccine adjuvant QS-21 production appeared first on Pharma Mirror Magazine.
Vaccine 130
130 
Let's personalize your content